Search clinical trials for: NBP607-TIV

Total 6916 results

SK Chemicals Co., Ltd.

Completed

Safety Study of NBP608 in Healthy Adult Volunteers

Immunization; Infection | Varicella Zoster

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

Influenza, Human

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

Influenza
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

Influenza

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents

Influenza, Human
SK Chemicals Co., Ltd.

Completed

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

Prevention of Influenza

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents

Influenza, Human
SK Chemicals Co., Ltd.

Completed

Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects

Influenza, Human
SK Chemicals Co., Ltd.

Completed

The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age

Varicella

Philippines
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

Varicella

Philippines
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Herpes Zoster

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Herpes Zoster

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine

Pneumococcal Infections
M.D. Anderson Cancer Center
vTv Therapeutics

Withdrawn

TTP607 in Refractory Solid Malignancies

Lymphoma | Advanced Cancers
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

Seasonal Influenza

Colombia, Mexico, Panama, Philippines
Butantan Institute
Butantan Foundation

Active, not recruiting

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

Influenza, Human

Brazil
McGill University Health Centre/Research Institute...
The Arthritis Society, Canada

Unknown

Standard Versus High Dose Inactivated Influenza Vaccine in RA (IV-RA)

Rheumatoid Arthritis

Canada
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP615 in Healthy Female

Cervical Cancer

Korea, Republic of
University of Oxford

Completed

ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses

Influenza

United Kingdom
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP606 in Healthy Toddlers

Pneumococcal Infections

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety Study of NBP606 in Healthy Infants

Pneumococcal Infections

Korea, Republic of
Novartis Vaccines

Completed

A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

Influenza

Italy, Spain
Canadian Immunization Research Network
CHU de Quebec-Universite Laval; McGill University Health Centre/Research Institute... and other collaborators

Completed

CT18 Infant Influenza Priming Study in Vaccine Naive Infants

Influenza

Canada
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Influenza
PT Bio Farma

Completed

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Safety Issues

Indonesia
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States
Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Novartis Pharmaceuticals

Terminated

Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa (ELIXIR)

Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis

Germany
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
C. R. Bard

Completed

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Vascular Access Complication

United States
Il-Yang Pharm. Co., Ltd.

Completed

Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults

Influenza, Human
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above

Influenza

Czech Republic, Philippines, South Africa, Thailand
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
Novartis Vaccines

Completed

Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

Influenza

Lithuania
University of Oxford

Completed

A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine

Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

Influenza

Poland
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Influenza

United States, Colombia, Panama, Philippines
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010

Influenza
Seqirus
Novartis Vaccines

Completed

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

Influenza Virus

United States, Canada, Finland, Italy, Mexico, Philippines, Poland, Puerto Rico, Spain, Taiwan, Thailand
MedImmune LLC
University of Pittsburgh; Passport Health

Completed

Assessing Choice in the Employer Setting (ACES) Study (MA181)

Healthy

United States
BioNTech SE
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

COVID-19 | Influenza, Human

United States
BiondVax Pharmaceuticals ltd.

Completed

Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

Influenza

Israel
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
MedImmune LLC

Completed

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Influenza

United States
Boehringer Ingelheim

Completed

Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers

Healthy
Shanghai Public Health Clinical Center

Unknown

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

HIV

China

3

Subscribe